HER3 overexpression and survival in solid tumors: A meta-analysis

Journal of the National Cancer Institute

Volumn 105, Issue 4, 2013, Pages 266-273

  Ocana, Alberto ^a,b   Vera Badillo, Francisco ^b   Seruga, Bostjan ^c   Templeton, Arnoud ^b   Pandiella, Atanasio ^d   Amir, Eitan ^b  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c INSTITUTE OF ONCOLOGY   (Slovenia)

^d Centro de Investigacion del Cancer   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AV 203; CABAZITAXEL; CARBOPLATIN; CETUXIMAB; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 3; ERLOTINIB; EXEMESTANE; HER3 PROTEIN; IRINOTECAN; MM 111; MM 121; PACLITAXEL; PEMETREXED; PLACEBO; RO 5479599; SAR 256212; TRASTUZUMAB; U 31287; UNCLASSIFIED DRUG; XL 147;

BREAST CANCER; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; COLORECTAL CANCER; DISEASE ASSOCIATION; DRUG DOSE ESCALATION; GENE OVEREXPRESSION; HEAD AND NECK CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; MANTEL HAENSZEL TEST; MEDLINE; MELANOMA; META ANALYSIS; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; PUBLICATION; REVIEW; SOLID TUMOR; STATISTICAL ANALYSIS; STOMACH CANCER; SURVIVAL TIME; UTERINE CERVIX CANCER;

BREAST NEOPLASMS; COLORECTAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; KAPLAN-MEIER ESTIMATE; MELANOMA; NEOPLASMS; ODDS RATIO; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTOR, ERBB-3; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84875048399     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djs501     Document Type: Review

References (37)

1. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2000;103(2): 211-225.
2. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2(2): 127-137.
3. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005;5(5): 341-354.
4. Ocana A, Pandiella A. Identifying breast cancer druggable oncogenic alterations: lessons learned and future targeted options. Clin Cancer Res. 2008;14(4): 961-970.
5. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353(2): 123-132.
6. Ocana A, Amir E, Seruga B, Martin M, Pandiella A. The evolving landscape of protein kinases in breast cancer: clinical implications [published online ahead of print June 13, 2012]. Cancer Treat Rev. 2012; doi: 10.1016/j. ctrv.2012.05.004.
7. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. Embo J. 2000;19(13): 3159-3167.
8. Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF 3rd, Hynes NE. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci U S A. 2003;100(15): 8933-8938.
9. Tzahar E, Waterman H, Chen X, et al. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol. 1996;16(10): 5276-5287.
10. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell. 2004;5(4): 317-328.
11. Montero JC, Rodriguez-Barrueco R, Ocana A, Diaz-Rodriguez E, Esparis-Ogando A, Pandiella A. Neuregulins and cancer. Clin Cancer Res. 2008;14(11): 3237-3241.
12. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer. 2009;9(7): 463-475.
13. Schoeberl B, Pace EA, Fitzgerald JB, et al. Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis. Sci Signal. 2009;2(77):ra31.
14. Baselga J, Cortes J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366(2): 109-119.
15. Schoeberl B, Faber AC, Li D, et al. An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation. Cancer Res. 2010;70(6): 2485-2494.
16. Liberati A, Altman D, Tetzlaff J. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;21;6(7): e1000100.
17. Deeks JJ, Higgins JPT, Altman DG. Analysing and presenting results. In: Higgins JPT, Green S, ed. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5. Chichester, UK: John Wiley & Sons; 2006.
18. Hirakawa T, Nakata B, Amano R, et al. HER3 overexpression as an independent indicator of poor prognosis for patients with curatively resected pancreatic cancer. Oncology. 2011;81(3-4): 192-198.
19. Spears M, Taylor KJ, Munro AF, et al. In situ detection of HER2:HER2 and HER2:HER3 protein-protein interactions demonstrates prognostic significance in early breast cancer. Breast Cancer Res Treat 2012;132(2): 463-470.
20. Witton CJ, Reeves JR, Going JJ, Cooke TG, Bartlett JM. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol. 2003;200(3): 290-297.
21. Kountourakis P, Pavlakis K, Psyrri A, et al. Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas. BMC Cancer. 2006;6(1): 46.
22. Baiocchi G, Lopes A, Coudry RA, et al. ErbB family immunohistochemical expression in colorectal cancer patients with higher risk of recurrence after radical surgery. Int J Colorectal Dis. 2009;24(9): 1059-1068.
23. Hayashi M, Inokuchi M, Takagi Y, et al. High expression of HER3 is associated with a decreased survival in gastric cancer. Clin Cancer Res. 2008;14(23): 7843-7849.
24. Beji A, Horst D, Engel J, Kirchner T, Ullrich A. Toward the prognostic significance and therapeutic potential of HER3 receptor tyrosine kinase in human colon cancer. Clin Cancer Res. 2012;18(4): 956-968.
25. Begnami MD, Fukuda E, Fregnani JH, et al. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome. J Clin Oncol. 2011;29(22): 3030-3036.
26. Reschke M, Mihic-Probst D, van der Horst EH, et al. HER3 is a determinant for poor prognosis in melanoma. Clin Cancer Res. 2008;14(16): 5188-5197.
27. Tanner B, Hasenclever D, Stern K, et al. ErbB-3 predicts survival in ovarian cancer. J Clin Oncol. 2006;24(26): 4317-4323.
28. Takikita M, Xie R, Chung JY, et al. Membranous expression of Her3 is associated with a decreased survival in head and neck squamous cell carcinoma. J Transl Med. 2011;9(29): 126.
29. Lee CM, Shrieve DC, Zempolich KA, et al. Correlation between human epidermal growth factor receptor family (EGFR, HER2, HER3, HER4), phosphorylated Akt (P-Akt), and clinical outcomes after radiation therapy in carcinoma of the cervix. Gynecol Oncol. 2005;99(2): 415-421.
30. Li Q, Wang D, Li J, Chen P. Clinicopathological and prognostic significance of HER-2/neu and VEGF expression in colon carcinomas. BMC Cancer. 2011;1(27): 277.
31. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA. Nonclinical studies addressing the mechanism of action of trastuzumab (herceptin). Semin Oncol. 1999;26(4 Suppl 12): 60-70.
32. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244(4905): 707-712.
33. Hsieh A, Moasser M. Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer. 2007;97(20): 453-457.
34. Sergina NV, Rausch M, Wang D, et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature. 2007;445(7126): 437-441.
35. Yuste L, Montero JC, Esparis-Ogando A, Pandiella A. Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin. Cancer Res. 2005;65(15): 6801-6810.
36. Sheng Q, Liu X, Fleming E, et al. An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell. 2010;17(3): 298-310.
37. Massagué J, Pandiella A. Membrane-anchored growth factors. Annu Rev Biochem. 1993;62: 515-541.